Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease

Miguel Regueiro*, Sandra El-Hachem, Kevin E. Kip, Wolfgang Schraut, Leonard Baidoo, Andrew Watson, Jason Swoger, Marc Schwartz, Arthur Barrie, Marilyn Pesci, David Binion

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Background Infliximab is effective treatment for Crohn's disease and has been associated with rare, but serious infectious complications. Emerging data suggest a benefit of infliximab in preventing postoperative Crohn's disease recurrence. It is not known whether administration of infliximab shortly after resective surgery for Crohn's disease increases postoperative complications. Aims To evaluate the risk of developing postoperative complications among Crohn's disease patients receiving infliximab within 4 weeks of intestinal resection. Methods As part of a randomized placebo-controlled infliximab postoperative prevention study, adverse events were prospectively monitored. Crohn's disease patients undergoing intestinal resection were randomized to placebo or infliximab 2-4 weeks after surgery. Study infusions were administered at 0, 2, and 6 weeks then every 8 weeks for 1 year. To evaluate whether infliximab increased postoperative complications, we analyzed all adverse events for 1 year after surgery. Results Twenty-four patients were randomized to infliximab or placebo after intestinal resection for Crohn's disease. Mean time to first postoperative infusion was 20 days (range 14-25 days). Over the course of 1 year, there were 22 total adverse events, but no difference between infliximab and placebo patients (12 versus 10, respectively, P = 1.0). In the immediate postoperative period, within 8 weeks of surgery, the number of adverse events was also similar between the two groups (3 infliximab and 5 placebo patients, P = 0.68). There were no serious adverse events and no complications related to wound healing or infection. Conclusions Initiation of infliximab within 4 weeks of intestinal resection was not associated with postoperative complications.

Original languageEnglish (US)
Pages (from-to)3610-3615
Number of pages6
JournalDigestive diseases and sciences
Issue number12
StatePublished - Dec 2011


  • Adverse events
  • Crohn's disease
  • Infliximab
  • Postoperative
  • Safety
  • Surgery

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease'. Together they form a unique fingerprint.

Cite this